Physicians' Academy for Cardiovascular Education

Lower bleeding risk with NOACs vs VKA in low-risk AF patients

Effectiveness and Safety of Standard-Dose Non vitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor - A Nationwide Cohort Study

Literature - Lip GYH, Skjøth F, Nielsen PB, et al. - JAMA Cardiol. 2017; published online ahead of print

Main results


In a Danish observational cohort study, the risk of an ischemic stroke or systemic embolism was similar between NOACs compared with warfarin in AF patients with a single non-sex stroke CHA2DS2-VASc risk factor. Lower mortality rates were seen for all NOACs compared with warfarin, but this appeared to be the consequence of selective prescription patterns. The risk of any bleeding was lower for apixaban and dabigatran compared with warfarin.

These data should be interpreted with caution because of possible residual unmeasured confounding due to selective prescribing and unobserved comorbidities, or other factors known to influence treatment selection that were not present in the data set.


Show references

Find this article online at JAMA Cardiology

Share this page with your colleagues and friends: